echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > FDA grants Bayer's oral FXIa inhibitor asundexian Fast Track designation!

    FDA grants Bayer's oral FXIa inhibitor asundexian Fast Track designation!

    • Last Update: 2022-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    By specifically targeting proteins involved in pathological thrombosis, but leaving pathways involved in physiological vascular healing intact, FXIa inhibitors can prevent events such as stroke and myocardial infarction (MI) without a corresponding increase in bleeding risk


    Bayer today announced that the U.


    Fast Track Designation (FTD) is designed to expedite the development and expedited review of drugs for serious diseases that address serious unmet medical needs in key areas


    asundexian is an oral factor XIa (FXIa) inhibitor currently being developed as a potential drug for secondary prevention in patients with NCIS, as well as 2 other diseases: atrial fibrillation (irregular heartbeat) and recent myocardial infarction (heart attack)


    Currently, Bayer is conducting Phase 2 clinical trials of asundexian in all 3 indications, either as monotherapy or in combination with antiplatelet therapy


    By specifically targeting proteins involved in pathological thrombosis, but leaving pathways involved in physiological vascular healing intact, FXIa inhibitors can prevent events such as stroke and myocardial infarction (MI) without a corresponding increase in bleeding risk


    The asundexian project aims to provide further support for the hypothesis that inhibition of FXIa with asundexian reduces the risk of thrombotic events without increasing the risk of bleeding


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.